Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B

Natera, Inc.

2024-FY EPS reported -$1.53 revenue$1,696,911,000

Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).
Q4 gross margin 62.9% vs 51.4% a year ago; FY2024 GM 60.3%.
Q4 net loss $53.8M ($0.41/share) vs $78.0M ($0.65) in Q4 2023; op loss $64.7M.
Oncology tests in Q4 150,800 (+54.7% YoY); total tests 792,800 (+26.5%).
FY2025 guidance: rev $1.87-1.95B; GM ~60-64%; positive net cash inflow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.